ESR1 and breast carcinoma: Preclinical results demonstrated inhibitory effects of tamoxifen on growth of ER+ tumors [55,56], and an extensive body of clinical evidence supports the efficacy of tamoxifen in treatment and risk reduction of breast cancer [57].